Turbine raised $25M Series B led by Interactive Venture Partners with participation from Beiersdorf...
The AMW Read
The article provides an incremental update to a player in the Vertical AI (Bio) segment via a mid-sized Series B round and market expansion.
NoveltySignificance
Healthcare & Bio · Player Map
Turbine raised $25M Series B led by Interactive Venture Partners with participation from Beiersdorf Venture Capital, marking their expansion into immunology through a new partnership with a top 10 pharma company. This validates virtual cell technology's ability to model complex biological systems beyond oncology, enabling scientists to screen millions of combination therapy candidates at computational speed rather than physical lab constraints. With the AI drug discovery market projected to reach $8-10B in 2026 and Turbine already supporting 30+ discovery programs across major pharma partners like MSD and AstraZeneca, this positions them as Central Europe's emerging leader in turning biology into an engineering discipline.
